Replay of
Preventing Cerebrospinal Fluid Leakage in Endonasal Surgery
November 19, 2008
17:00 CET
From Università degli Studi di Napoli Federico II in Naples, Italy
On Wednesday, November 19, Professor Paolo Cappabianca from Università degli Studi di Napoli Federico II in Naples, Italy, and Mr. Michael Powell from National Hospital, Queen Square London, will present on endoscopic and microscopic pituitary tumor removal and CSF leak avoidance and repair techniques. During the program, participants can send questions via email, and they will be answered during the broadcast.
This program features DuraSealTM dural sealant. It is intended for audiences outside the United States where Duraseal has CE Mark approval and is indicated for use as an adjunct to standard methods of dural repair, such as sutures, to provide watertight closure, including endonasal procedures. Duraseal (U.S.) clinical studies were assessed based on frontal, temporal, parietal, occipital and suboccipital approaches only. The endonasal approach was not studied as part of the U.S. clinical trial and is not approved in the U.S.
This program is sponsored by COVIDIEN Biosurgery.
On Wednesday, November 19, Professor Paolo Cappabianca from Università degli Studi di Napoli Federico II in Naples, Italy, and Mr. Michael Powell from National Hospital, Queen Square London, will present on endoscopic and microscopic pituitary tumor removal and CSF leak avoidance and repair techniques. During the program, participants can send questions via email, and they will be answered during the broadcast.
This program features DuraSealTM dural sealant. It is intended for audiences outside the United States where Duraseal has CE Mark approval and is indicated for use as an adjunct to standard methods of dural repair, such as sutures, to provide watertight closure, including endonasal procedures. Duraseal (U.S.) clinical studies were assessed based on frontal, temporal, parietal, occipital and suboccipital approaches only. The endonasal approach was not studied as part of the U.S. clinical trial and is not approved in the U.S.
This program is sponsored by COVIDIEN Biosurgery.
